The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo ... shortly after the approval of GSK's recombinant RSVPreF3 ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Respiratory Syncytial Virus Vaccine, Adjuvanted, contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for seniors. Carina Marquez, MD, associate professor of Medicine in ...

RSV vaccines effective, but more people need to get them Date: October 28, 2024 Source: University of Rochester Medical Center Summary: Doctors detail what we learned after the first season ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

More information: Angela R Branche, Real-world effectiveness studies of the benefit of RSV vaccines, The Lancet (2024).DOI: 10.1016/S0140-6736(24)02150-0 Amanda B Payne et al, Respiratory ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...